Presenilin1 Gene Characteristics Used as Alzheimer's Disease Biomarker

The Presenilin1 (PSEN1) gene encodes the catalytic peptide of the γ-secretase complex, a key enzyme that cleaves the amyloid-β protein precursor (AβPP), to generate the amyloid-β (Aβ) peptides, involved in Alzheimer’s Disease (AD). Other substrates of the γ-secretase, such as E-cadherin and Notch1, are involved in neurodevelopment and hematopoiesis.

A team of international scientists working with the Sapienza University of Rome (Rome, Italy) analyzed patterns of DNA modification that affect the expression of the PSEN1 gene during brain development and during the progression of Alzheimer's in mice. They checked the results in humans by analyzing post-mortem human brain tissue from Alzheimer's patients and from prenatal and postnatal babies and adolescents. To see whether changes to DNA methylation could be detected in human blood, they analyzed blood samples from 20 patients with late-onset Alzheimer's disease, comparing the results to 20 healthy controls.

Assessment of CpG and non-CpG DNA methylation was performed by bisulphite DNA modification and genomic sequencing using non-CpG Methylation-Insensitive Primers (MIPs), previously described (HSPS1BisF1 and HSPS1BisR1 for the human DNA, MMPS1BisF1). Sequencing reactions of purified plasmid DNA were performed by the cycle sequencing method using the ABI PRISM 3130xl genetic analyzer (Applied Biosystems, Foster City, CA, USA). Total RNA was extracted using the QIAGEN RNeasy Lipid Tissue mini kit and the QIAcube Connect instrument (QIAGEN, Hilden, Germany).

The results from post-mortem human brain tissue found upregulation of the PSEN1 gene in Alzheimer's patients. In both sexes, there was a significant inverse relationship between the extent of gene expression and DNA methylation. The analysis of blood samples was able to detect lower PSEN1-related DNA methylation in Alzheimer's patients compared to controls. The difference was significant, although not as large as in brain samples. As lower methylation was detectable in the blood, and is associated with higher expression of PSEN1, it could offer a new way to diagnose Alzheimer's early, and less invasively, than sampling brain tissue.

Andrea Fuso, PhD an assistant professor and senior author of the study, said, “We've detected an early sign of the disease in a DNA modification, or epigenetic marker, that was previously overlooked, and that could even provide a starting point for developing new therapies, as well as earlier diagnosis. Our results offer an exciting new area of investigation, deploying the methods we used to study DNA methylation so that modifications won't be missed. If found to be causal, our findings would provide a starting point for developing epigenetic therapies.” The study was published on February 5, 2020 in the journal Epigenetics.

Related Links:
Sapienza University of Rome
Applied Biosystems
QIAGEN